熱門資訊> 正文

Vanda Pharmaceuticals因VGT-1849 B获得FDA孤儿药地位

2025-08-28 22:08

Vanda Pharmaceuticals (NASDAQ:VNDA) said that the U.S. FDA has granted orphan drug designation for its experimental drug candidate, VGT-1849B, for the treatment of polycythemia vera.
With its orphan drug designation, the FDA aims to offer financial incentives to drug developers targeting rare diseases and conditions.
VNDA shares are up 1.5% in morning trade.

More on Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript
Vanda asks FDA's Makary to review approval of Hetlioz generics
Vanda says court ruling opens door for Hetlioz jet lag indication
Seeking Alpha’s Quant Rating on Vanda Pharmaceuticals
Historical earnings data for Vanda Pharmaceuticals

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。